Selected article for: "cancer type and solid tumor"
Author: Abdul-Jawad, Sultan; Baù, Luca; Alaguthurai, Thanussuyah; del Molino del Barrio, Irene; Laing, Adam G.; Hayday, Thomas S.; Monin, Leticia; Muñoz-Ruiz, Miguel; McDonald, Louisa; Francos Quijorna, Isaac; McKenzie, Duncan; Davis, Richard; Lorenc, Anna; Chan, Julie Nuo En; Ryan, Sarah; Bugallo-Blanco, Eva; Yorke, Rozalyn; Kamdar, Shraddha; Fish, Matthew; Zlatareva, Iva; Vantourout, Pierre; Jennings, Aislinn; Gee, Sarah; Doores, Katie; Bailey, Katharine; Hazell, Sophie; De Naurois, Julien; Moss, Charlotte; Russell, Beth; Khan, Aadil A.; Rowley, Mark; Benjamin, Reuben; Enting, Deborah; Alrifai, Doraid; Wu, Yin; Zhou, You; Barber, Paul; Ng, Tony; Spicer, James; Van Hemelrijck, Mieke; Kumar, Mayur; Vidler, Jennifer; Lwin, Yadanar; Fields, Paul; Karagiannis, Sophia N.; Coolen, Anthony C.C.; Rigg, Anne; Papa, Sophie; Hayday, Adrian C.; Patten, Piers E.M.; Irshad, Sheeba
Title: Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients
  • Cord-id: 0dckpgj6
  • Document date: 2021_1_5
    • ID: 0dckpgj6
    Snippet: Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19(+) non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively
    Document: Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19(+) non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. Furthermore, while recovered solid cancer patients' immunophenotypes resemble those of non-virus-exposed cancer patients, recovered hematological cancer patients display distinct, lingering immunological legacies. Thus, while solid cancer patients, including those with advanced disease, seem no more at risk of SARS-CoV-2-associated immune dysregulation than the general population, hematological cancer patients show complex immunological consequences of SARS-CoV-2 exposure that might usefully inform their care.

    Search related documents:
    Co phrase search for related documents
    • active cancer and low number: 1, 2, 3
    • active cancer and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36
    • active cancer and lung cancer patient: 1
    • active cancer and lymphocyte count: 1, 2, 3
    • active cancer and lymphocyte neutrophil: 1, 2, 3, 4
    • active cancer and lymphocyte neutrophil ratio: 1, 2
    • active cancer and lymphocyte platelet: 1
    • active cancer and lymphocytic leukemia: 1, 2
    • active cancer patient and acute respiratory syndrome: 1
    • active cancer patient and lung cancer: 1, 2
    • active cancer patient and lung cancer patient: 1
    • active cancer treatment and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active cancer treatment and low number: 1, 2
    • active cancer treatment and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • active cancer treatment and lung cancer patient: 1
    • active cancer treatment and lymphocyte count: 1